U.S. markets closed
  • S&P Futures

    3,829.75
    -4.25 (-0.11%)
     
  • Dow Futures

    30,894.00
    -42.00 (-0.14%)
     
  • Nasdaq Futures

    11,806.25
    -2.25 (-0.02%)
     
  • Russell 2000 Futures

    1,737.90
    -3.80 (-0.22%)
     
  • Crude Oil

    99.95
    +0.45 (+0.45%)
     
  • Gold

    1,767.50
    +3.60 (+0.20%)
     
  • Silver

    19.12
    -0.00 (-0.01%)
     
  • EUR/USD

    1.0266
    -0.0004 (-0.04%)
     
  • 10-Yr Bond

    2.8090
    -0.0800 (-2.77%)
     
  • Vix

    27.54
    +0.01 (+0.04%)
     
  • GBP/USD

    1.1964
    +0.0013 (+0.11%)
     
  • USD/JPY

    135.2400
    -0.6020 (-0.44%)
     
  • BTC-USD

    19,872.39
    -393.98 (-1.94%)
     
  • CMC Crypto 200

    430.07
    -9.95 (-2.26%)
     
  • FTSE 100

    7,025.47
    -207.18 (-2.86%)
     
  • Nikkei 225

    26,075.73
    -347.74 (-1.32%)
     

Earnings Estimates Moving Higher for Albemarle (ALB): Time to Buy?

  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.
·2 min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.

Albemarle (ALB) could be a solid addition to your portfolio given a notable revision in the company's earnings estimates. While the stock has been gaining lately, the trend might continue since its earnings outlook is still improving.

The upward trend in estimate revisions for this specialty chemicals company reflects growing optimism of analysts on its earnings prospects, which should get reflected in its stock price. After all, empirical research shows a strong correlation between trends in earnings estimate revisions and near-term stock price movements. Our stock rating tool -- the Zacks Rank -- is principally built on this insight.

The five-grade Zacks Rank system, which ranges from a Zacks Rank #1 (Strong Buy) to a Zacks Rank #5 (Strong Sell), has an impressive externally-audited track record of outperformance, with Zacks #1 Ranked stocks generating an average annual return of +25% since 2008.

Consensus earnings estimates for the next quarter and full year have moved considerably higher for Albemarle, as there has been strong agreement among the covering analysts in raising estimates.

The chart below shows the evolution of forward 12-month Zacks Consensus EPS estimate:

12 Month EPS

Current-Quarter Estimate Revisions

For the current quarter, the company is expected to earn $2.65 per share, which is a change of +197.75% from the year-ago reported number.

Over the last 30 days, three estimates have moved higher for Albemarle while one has gone lower. As a result, the Zacks Consensus Estimate has increased 7.52%.

Current-Year Estimate Revisions

For the full year, the company is expected to earn $12.63 per share, representing a year-over-year change of +212.62%.

In terms of estimate revisions, the trend for the current year also appears quite encouraging for Albemarle. Over the past month, five estimates have moved higher compared to no negative revisions, helping the consensus estimate increase 20.61%.

Favorable Zacks Rank

Thanks to promising estimate revisions, Albemarle currently carries a Zacks Rank #1 (Strong Buy). The Zacks Rank is a tried-and-tested rating tool that helps investors effectively harness the power of earnings estimate revisions and make the right investment decision. You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here.

Our research shows that stocks with Zacks Rank #1 (Strong Buy) and 2 (Buy) significantly outperform the S&P 500.

Bottom Line

While strong estimate revisions for Albemarle have attracted decent investments and pushed the stock 13.3% higher over the past four weeks, further upside may still be left in the stock. So, you may consider adding it to your portfolio right away.


Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
 
Albemarle Corporation (ALB) : Free Stock Analysis Report
 
To read this article on Zacks.com click here.
 
Zacks Investment Research